GOTHENBURG, Sweden — Multi4 Medical, a pioneering medical technology company, today announced the publication of its landmark clinical research in BJU International (BJUI), one of the world’s most prestigious and high-impact urology journals. The peer-reviewed study, "First-in-human outpatient management of recurrent NMIBC with the Multi4 instrument," details the complete development journey—from initial concept and prototype through preclinical and clinical validation—culminating in the world's first all-in-one instrument for outpatient bladder cancer management that performs both therapeutic treatment and diagnostic tissue sampling in a single, rapid procedure.
In parallel with this publication, Multi4 Medical has initiated its first patient treatments in Sweden, following the receipt of its CE-mark approval earlier this year.
The study, conducted at Sahlgrenska University Hospital under the leadership of Dr. Henrik Kjölhede (Department of Urology) in collaboration with Joakim Håkansson at RISE (Research Institutes of Sweden), demonstrates that patients with Non-Muscle Invasive Bladder Cancer (NMIBC) can be successfully and safely treated with the Multi4 System in an office-based outpatient setting, completely eliminating the need for general anesthesia, operating rooms (ORs), or hospitalization.